Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 01'st May 2025
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescr
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellul
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
11:15pm, Monday, 24'th Feb 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
12:25pm, Monday, 24'th Feb 2025
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
10:10am, Friday, 21'st Feb 2025
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.30 per share a year ago.
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
08:00am, Friday, 21'st Feb 2025
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
02:35pm, Tuesday, 21'st Jan 2025
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
12:10pm, Thursday, 16'th Jan 2025
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
09:56am, Tuesday, 14'th Jan 2025
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?
08:01am, Tuesday, 14'th Jan 2025
Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellul
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Joh
BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
02:23pm, Monday, 13'th Jan 2025
Intra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%)
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz
12:41pm, Monday, 13'th Jan 2025
Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.
Drugmakers rush to sign deals on first day of industry conference
12:07pm, Monday, 13'th Jan 2025
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.
